Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Profit After Tax: 2022-2024

Historic Profit After Tax for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $65.6 million.

  • Entrada Therapeutics' Profit After Tax fell 214.52% to -$44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.27%. This contributed to the annual value of $65.6 million for FY2024, which is 1081.69% up from last year.
  • Per Entrada Therapeutics' latest filing, its Profit After Tax stood at $65.6 million for FY2024, which was up 1,081.69% from -$6.7 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Profit After Tax registered a high of $65.6 million during FY2024, and its lowest value of -$94.6 million during FY2022.
  • Its 3-year average for Profit After Tax is -$11.9 million, with a median of -$6.7 million in 2023.
  • Data for Entrada Therapeutics' Profit After Tax shows a peak YoY surged of 1,081.69% (in 2024) over the last 5 years.
  • Entrada Therapeutics' Profit After Tax (Yearly) stood at -$94.6 million in 2022, then soared by 92.93% to -$6.7 million in 2023, then soared by 1,081.69% to $65.6 million in 2024.